Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

Laureate Pharma and Neoprobe sign manufacturing agreement

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, and Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that they have entered into a Biopharmaceutical Development and Manufacturing Agreement.

9 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Screening rates for colorectal cancer are lower in safety net health system, study reveals

Colorectal cancer screening rates are much lower among those in a safety net health system compared to the national average, and the number one predictor of screening is a combination of regular visits and insurance access.

8 Sep 2009

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston.

4 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

Weight gain in men linked with risk of prostate cancer

Body mass in younger and older adulthood, and weight gain between these periods of life, may influence a man's risk for prostate cancer. This risk varies among different ethnic populations, according to results of a study in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

2 Sep 2009

InfuSystem Holdings appoints Board Chairman as new Chief Executive Officer

InfuSystem Holdings, Inc., announced today that its Board of Directors has accepted the resignation of Mr. Steve Watkins as President, Chief Executive Officer and Board Member, effective September 7, 2009. Sean McDevitt, Chairman of the Board, will immediately take over the additional role of Chief Executive Officer.

1 Sep 2009

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Barrier-focused intervention program to increase colonoscopy attendance

In view of low attendance rate for colonoscopy screening for colorectal cancer (CRC), it is necessary to establish effective intervention methods to increase colonoscopy compliance. Many studies have reported that subjective or objective barriers prevent high-risk subjects from undergoing colonoscopy examination, which indicates that barrier-focused intervention might be effective. However, such barrier-focused intervention has not been reported in China.

27 Aug 2009

Studies suggest that serrated polyps can be precursors of colon cancers

Serrated colorectal polyps include the subgroups hyperplastic polyps, sessile serrated polyps (also called sessile serrated adenomas), and serrated adenomas. Recent studies have found that serrated polyps share molecular features with a subgroup of colon cancers, leading to the hypothesis that serrated polyps can be precursors of cancer through a hyperplastic polyp to serrated adenoma to cancer sequence.

26 Aug 2009

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Ho Jeong and his colleague from Korea presented a case of duodenal obstruction after successful selective transcatheter arterial embolization (TAE) for a duodenal diverticular hemorrhage. Their study will be published on August 14, 2009 in the World Journal of Gastroenterology.

26 Aug 2009

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.

26 Aug 2009

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure.

25 Aug 2009

New noninvasive technique to detect colorectal and gastric cancers found

A preliminary evaluation of methylation of two gene promoters in fecal DNA showed promise as a noninvasive method to detect colorectal and gastric cancers, according to a new study published online August 21 in the Journal of the National Cancer Institute.

24 Aug 2009

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalised medication is increasingly common.

24 Aug 2009

AMDL Diagnostics to focus on in vitro diagnostic cancer tests

AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced the inauguration of AMDL Diagnostics Inc. (ADI), a new wholly-owned subsidiary that will focus on the research, development, manufacture and international sales of Onko-Sure(TM)-- AMDL's proprietary, regulatory approved in vitro diagnostic (IVD) cancer test.

21 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Forty-six uninsured San Diego County patients to receive free surgeries, procedures

Forty-six uninsured San Diego County patients will receive donated outpatient surgeries and procedures on Saturday, August 22, 2009, through an ongoing partnership between Project Access San Diego (PASD), a program of the San Diego County Medical Society Foundation, Kaiser Permanente and the Alliance Healthcare Foundation. PASD mobilizes medical volunteers to provide free surgeries and procedures to uninsured San Diegans.

19 Aug 2009

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Laureate Pharma and Neoprobe sign manufacturing agreement

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

Screening rates for colorectal cancer are lower in safety net health system, study reveals

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Hope for limiting skin toxicity of cancer drug users

Weight gain in men linked with risk of prostate cancer

InfuSystem Holdings appoints Board Chairman as new Chief Executive Officer

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

Barrier-focused intervention program to increase colonoscopy attendance

Studies suggest that serrated polyps can be precursors of colon cancers

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

New noninvasive technique to detect colorectal and gastric cancers found

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

AMDL Diagnostics to focus on in vitro diagnostic cancer tests

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Forty-six uninsured San Diego County patients to receive free surgeries, procedures

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Newsletters you may be interested in